News Some good news for BMS with Opdivo + natural killer cell com... But BMS dumps combination with Yervoy.
ESMO2016 Cancer market commentary: 3 highlights from ESMO (Part 1) Commentary on key cancer data from ESMO by Stephanie Hawthorne
ESMO2016 Eye on ESMO: Day 1 - Access in spotlight before data deluge Europe's biggest cancer conference ESMO is underway
Views & Analysis Immuno-oncology: how to keep ahead in a fast-moving field In the last two years, the first PD-1 checkpoint inhibitor drugs to reach patients have launched a revolution in cancer care.
News Teva buys US rights to Celltrion biosimilars Israeli firm buys rights to near-copies of Roche blockbusters.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
